Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07128550) titled 'A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide' on Aug. 13.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Vir Biotechnology, Inc.
Condition:
Viral Hepatitis
Intervention:
Drug: Tobevibart
Drug: Elebsiran
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: July 30, 2025
Target Sample Size: 150
Countries of Recruitment:
France
Romania
United Kingdom
France
Romania
United K...